Craig S Brown1, Andrea T Obi2, Jack L Cronenwett3, Lowell Kabnick4, Thomas W Wakefield2, Nicholas H Osborne2. 1. Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, Mich. Electronic address: brcraig@med.umich.edu. 2. Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, Mich. 3. Section of Vascular Surgery, Department of Surgery, Dartmouth Institute and Dartmouth-Hitchcock Medical Center, Lebanon, NH. 4. Atlantic Health System (Morristown Medical Center), Kabnick Vein Center, Morristown, NJ.
Abstract
OBJECTIVE: Many insurance payers are hesitating to cover interventional treatments in patients with isolated symptomatic varicose veins. In this study, we sought to determine the outcomes of patients with varicose veins who were treated with venous ablation alone or ablation plus phlebectomy using the Vascular Quality Initiative Varicose Vein Registry. METHODS: Using data from the Varicose Vein Registry between January 2015 and March 2019, we investigated immediate postoperative as well as long-term clinical and patient-reported outcomes among patients with documented symptomatic C2 disease undergoing truncal endovenous ablations alone and combined ablation and phlebectomy. Preprocedural and postprocedural comparisons were performed using t-test, χ2 test, or nonparametric tests when appropriate. Multivariable ordinal logistic regression was performed on ordinal outcome variables. RESULTS: Among 3375 patients with symptomatic C2 disease, 40.1% of patients (1376) underwent isolated truncal ablation and 59.9% (1999) underwent ablation and phlebectomy. Complications overall were low (8.6%) and varied between 8.4% and 8.7% in patients undergoing ablation alone and ablation plus phlebectomy, respectively (P = .820). The most common complication noted was paresthesia, 3.4% overall, which occurred more commonly after ablation and phlebectomy (4.5%) than after ablation alone (1.3%; P < .001). An improvement in Venous Clinical Severity Score (VCSS) was experienced by 87.4% of patients; median change in VCSS was 4 points (interquartile range [IQR], 2-5 points), with an improvement of 3 points among patients undergoing ablation alone (IQR, 1-5 points) and 5 points among patients undergoing ablation and phlebectomy (IQR, 3-5 points; P < .001). An improvement in overall symptoms was experienced by 94.4% of patients (median improvement, 11 points; (maximum, 30 points), with more significant decreases among patients undergoing ablation and phlebectomy (median, 12 points; IQR, 8-17 points) compared with ablation alone (median, 9 points; IQR, 5-13 points; P < .001). CONCLUSIONS: Among patients with isolated symptomatic varicose veins (C2 disease), ablation and ablation with phlebectomy are safe and effective in improving both patient-reported outcomes and clinical severity (VCSS). Given these data, payers should continue to cover these treatments.
OBJECTIVE: Many insurance payers are hesitating to cover interventional treatments in patients with isolated symptomatic varicose veins. In this study, we sought to determine the outcomes of patients with varicose veins who were treated with venous ablation alone or ablation plus phlebectomy using the Vascular Quality Initiative Varicose Vein Registry. METHODS: Using data from the Varicose Vein Registry between January 2015 and March 2019, we investigated immediate postoperative as well as long-term clinical and patient-reported outcomes among patients with documented symptomatic C2 disease undergoing truncal endovenous ablations alone and combined ablation and phlebectomy. Preprocedural and postprocedural comparisons were performed using t-test, χ2 test, or nonparametric tests when appropriate. Multivariable ordinal logistic regression was performed on ordinal outcome variables. RESULTS: Among 3375 patients with symptomatic C2 disease, 40.1% of patients (1376) underwent isolated truncal ablation and 59.9% (1999) underwent ablation and phlebectomy. Complications overall were low (8.6%) and varied between 8.4% and 8.7% in patients undergoing ablation alone and ablation plus phlebectomy, respectively (P = .820). The most common complication noted was paresthesia, 3.4% overall, which occurred more commonly after ablation and phlebectomy (4.5%) than after ablation alone (1.3%; P < .001). An improvement in Venous Clinical Severity Score (VCSS) was experienced by 87.4% of patients; median change in VCSS was 4 points (interquartile range [IQR], 2-5 points), with an improvement of 3 points among patients undergoing ablation alone (IQR, 1-5 points) and 5 points among patients undergoing ablation and phlebectomy (IQR, 3-5 points; P < .001). An improvement in overall symptoms was experienced by 94.4% of patients (median improvement, 11 points; (maximum, 30 points), with more significant decreases among patients undergoing ablation and phlebectomy (median, 12 points; IQR, 8-17 points) compared with ablation alone (median, 9 points; IQR, 5-13 points; P < .001). CONCLUSIONS: Among patients with isolated symptomatic varicose veins (C2 disease), ablation and ablation with phlebectomy are safe and effective in improving both patient-reported outcomes and clinical severity (VCSS). Given these data, payers should continue to cover these treatments.
Authors: G Marsden; M Perry; A Bradbury; N Hickey; K Kelley; H Trender; D Wonderling; A H Davies Journal: Eur J Vasc Endovasc Surg Date: 2015-10-02 Impact factor: 7.069
Authors: C Wittens; A H Davies; N Bækgaard; R Broholm; A Cavezzi; S Chastanet; M de Wolf; C Eggen; A Giannoukas; M Gohel; S Kakkos; J Lawson; T Noppeney; S Onida; P Pittaluga; S Thomis; I Toonder; M Vuylsteke; P Kolh; G J de Borst; N Chakfé; S Debus; R Hinchliffe; I Koncar; J Lindholt; M V de Ceniga; F Vermassen; F Verzini; M G De Maeseneer; L Blomgren; O Hartung; E Kalodiki; E Korten; M Lugli; R Naylor; P Nicolini; A Rosales Journal: Eur J Vasc Endovasc Surg Date: 2015-04-25 Impact factor: 7.069
Authors: Elna Masuda; Kathleen Ozsvath; John Vossler; Karen Woo; Robert Kistner; Fedor Lurie; Dan Monahan; William Brown; Nicos Labropoulos; Michael Dalsing; Neil Khilnani; Thomas Wakefield; Peter Gloviczki Journal: J Vasc Surg Venous Lymphat Disord Date: 2020-03-03
Authors: Andrea T Obi; Bradley N Reames; Trent J Rook; Sandford O Mouch; Arya Zarinsefat; Cathy Stabler; John E Rectenwald; Dawn M Coleman; Thomas W Wakefield Journal: Phlebology Date: 2015-09-15 Impact factor: 1.740
Authors: Andrea T Obi; Danielle C Sutzko; Jose I Almeida; Lowell Kabnick; Jack L Cronenwett; Nicholas H Osborne; Brajesh K Lal; Thomas W Wakefield Journal: J Vasc Surg Venous Lymphat Disord Date: 2017-05
Authors: Ahmed Hassanin; Thomas M Aherne; Garrett Greene; Emily Boyle; Bridget Egan; Sean Tierney; Stewart R Walsh; Seamus McHugh; Sayed Aly Journal: J Vasc Surg Venous Lymphat Disord Date: 2019-11